Demographic and clinical characteristics of patients with SAA in the study
| Variable . | N (%) . |
|---|---|
| No. of patients | 197 |
| Recipient age, y | |
| Median | 15 |
| Range | 0.5-40 |
| Donor age, y | |
| Median | 37 |
| Range | 20-55 |
| Male sex | 104 (54.7) |
| Disease subtype | |
| Acquired SAA | 133 (67.5) |
| Fanconi anemia | 57 (28.9) |
| Diamond-Blackfan anemia | 7 (3.6) |
| Myeloablative regimens | 98 (49.7) |
| White race | 149 (75.6) |
| Karnofsky performance status 90-100 | 151 (76.6) |
| Year of HCT | |
| 1988-1995 | 63 (33.2) |
| 1996-1999 | 73 (38.4) |
| 2000-2004 | 54 (28.4) |
| Died during follow-up | 135 (68.5) |
| Cause of death | |
| Infection | 35 |
| Acute or chronic GVHD | 24 |
| Primary or secondary graft failure | 14 |
| Other causes* | 62 |
| Variable . | N (%) . |
|---|---|
| No. of patients | 197 |
| Recipient age, y | |
| Median | 15 |
| Range | 0.5-40 |
| Donor age, y | |
| Median | 37 |
| Range | 20-55 |
| Male sex | 104 (54.7) |
| Disease subtype | |
| Acquired SAA | 133 (67.5) |
| Fanconi anemia | 57 (28.9) |
| Diamond-Blackfan anemia | 7 (3.6) |
| Myeloablative regimens | 98 (49.7) |
| White race | 149 (75.6) |
| Karnofsky performance status 90-100 | 151 (76.6) |
| Year of HCT | |
| 1988-1995 | 63 (33.2) |
| 1996-1999 | 73 (38.4) |
| 2000-2004 | 54 (28.4) |
| Died during follow-up | 135 (68.5) |
| Cause of death | |
| Infection | 35 |
| Acute or chronic GVHD | 24 |
| Primary or secondary graft failure | 14 |
| Other causes* | 62 |
Other causes of death include: hemorrhage, n = 16; acute respiratory distress syndrome or interstitial pneumonitis, n = 13; toxicity, n = 10; organ failure, n = 8; cancers, n = 3; and missing, n = 12.